Prima Mente is set to initiate a clinical trial deploying its Pleiades whole-epigenome platform to stratify Alzheimer’s patients for optimized management. Utilizing machine learning-enabled biological foundation models that capture DNA methylation signatures, the trial targets improved biomarker discovery and patient triage. The approach aims to overcome heterogeneity and early pathology detection challenges inherent in neurodegenerative diseases, with partnerships involving diagnostics and academic collaborators poised to be announced concomitant with study start.